Product
Erlotinib plus sulindac
1 clinical trial
1 indication
Indication
Head and Neck Squamous Cell CarcinomaClinical trial
Phase II Study of TARCEVA (Erlotinib) as Adjuvant Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma With Evaluation of Neoadjuvant Biomarker Modulation With TARCEVA vs. TARCEVA Plus SulindacStatus: Completed, Estimated PCD: 2014-09-01